deltatrials
Completed OBSERVATIONAL NCT06151379

Muscle Parameters and Pathological Response in Breast Cancer Patients

The Relation Between the Initial Value of the Skeletal Mass Index and Pathological Response

Sponsor: Acıbadem Atunizade Hospital

Interventions Neoadjuvant therapy
Updated 4 times since 2023 Last updated: Nov 21, 2023 Started: Mar 1, 2023 Primary completion: Sep 30, 2023 Completion: Oct 20, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06151379, this observational or N/A phase trial focuses on Neoadjuvant Chemotherapy and remains completed. Sponsored by Acıbadem Atunizade Hospital, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

4 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Dec 2023 — Jul 2024 [monthly]

    Completed

    First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acıbadem Atunizade Hospital
Data source: Acıbadem Atunizade Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations